The use of calcitonin gene-related peptide (CGRP) inhibitors to treat adults with migraine is linked to a 25% lower risk for ...

A type of drug used to prevent migraine may be associated with a reduced risk of glaucoma, according to a study published in ...

As estrogen levels fluctuate, a new study has found for female participants with migraine, their levels of the protein calcitonin gene-related peptide (CGRP) that plays a key role in starting the ...

Lower glaucoma rates emerge in large migraine cohort study ...

Since first introduced, anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies and CGRP antagonists (gepants) have had a transformative impact on migraine management, both preventive and ...

Key finding: Migraine patients on monoclonal antibody CGRP inhibitors had a 25% lower glaucoma risk over three years compared with other preventive therapies. Mechanism insight: The drugs may protect ...

One class of drugs has already found success in treating the painful, disorienting and common attacks. Excitement is building about a slew of additional drug targets. By Amber Dance/Knowable Magazine ...

The approval of medicines called “CGRP antagonists” has led to big changes in how migraines are managed. These medicines work in a different way than older medicines to treat or prevent migraine. The ...

The FDA expanded the indication for fremanezumab (Ajovy) injection for episodic migraine prevention to include children and adolescents, Teva Pharmaceuticals announced. Fremanezumab can now be used to ...